Lexicon Pharmaceuticals, Inc. (LXRX): Free Cash Flow
-$67.85M
Year ended 2025-12-31
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$67.85M | n/m | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | -$179.81M | n/m | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | -$162.37M | n/m | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | -$90.18M | n/m | 2025-03-07, From 2022-01-01 |
| 2021-12-31 | -$88.24M | n/m | 2024-03-25, From 2021-01-01 |
| 2020-12-31 | -$143.06M | n/m | 2023-03-03, From 2020-01-01 |
| 2019-12-31 | $113.74M | n/m | 2022-03-10, From 2019-01-01 |
| 2018-12-31 | -$148.70M | n/m | 2021-03-12, From 2018-01-01 |
| 2017-12-31 | -$185.62M | n/m | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | -$175.86M | n/m | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | $183.87M | n/m | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | -$75.70M | n/m | 2017-03-06, From 2014-01-01 |
| 2013-12-31 | -$92.80M | n/m | 2016-03-11, From 2013-01-01 |
| 2012-12-31 | -$94.95M | n/m | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | -$89.14M | n/m | 2014-03-07, From 2011-01-01 |
| 2010-12-31 | -$83.50M | n/m | 2013-03-11, From 2010-01-01 |
| 2009-12-31 | -$89.39M | n/a | 2012-03-08, From 2009-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$67.85M | n/m |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$171.34M | n/m |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | -$216.89M | n/m |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | -$33.54M | n/m |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $56.08M | -69.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $109.67M | n/m |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | -$377.29M | n/m |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $1.87M | +380.5% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | -$208.68M | n/m |
Compare LXRX, GOSS, OCUL, QTTB side by side · Screen every company in Pharmaceutical Preparations ↗